Clinical Trial Update: Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating carboplatin/nab-paclitaxel with pembrolizumab in non-small cell lung cancer was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Nisha Mohindra, MD | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-10-14